CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...